Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 4/20 | 0.76 |
| ▸ | TERT | O14746 | 4/20 | 0.57 |
| ▸ | CYCS | P99999 | 3/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29961137 | 0.98 | TOP1 (0.78) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL245937 | 0.98 | TOP1 (0.78) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL31315103 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| Magnesium SCHEMBL31258521 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| Hydrochloric Acid SCHEMBL31627581 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL31313616 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL31313985 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL600975 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| Hydrochloric Acid SCHEMBL2101556 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL30915394 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111013661-B | MOF @ POP core-shell material and application thereof in preparation of cyclic carbonate | 辽宁大学 | 2022-07-19 | — | — | CN | claimed |
| CN-111013661-B | MOF @ POP core-shell material and application thereof in preparation of cyclic carbonate | 辽宁大学 | 2022-07-19 | — | — | CN | disclosed |
| CN-111013661-B | MOF @ POP core-shell material and application thereof in preparation of cyclic carbonate | 辽宁大学 | 2022-07-19 | — | — | CN | disclosed |
| US-8436031-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1524974-A4 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARM INNC (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1742637-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006076009-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1558341-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050124678-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1524974-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004041209-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004001058-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030229065-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | TOP1 1534/4885TERT 1055/4885CYCS 4002/4885 |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | TOP1 1534/4885TERT 1055/4885CYCS 4002/4885 |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | TOP1 1534/4885TERT 1055/4885CYCS 4002/4885 |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JUN, CREBBP, TFEB | TOP1 1534/4885TERT 1055/4885CYCS 4002/4885 |
| US-20030229065-A1 | Transcription factor modulating compounds and methods of use thereof | RELA, ATF4, JUN | TOP1 1570/4885TERT 204/4885CYCS 4368/4885 |
| US-20050124678-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | TOP1 1534/4885TERT 1055/4885CYCS 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.